CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Whole Body Dual XRay Absorptiometry to Determine Body Composition

This policy covers coverage stance and coding for whole-body DXA body composition studies and governs Medicare Advantage and Commercial products under Blue Cross Blue Shield - Rhode Island.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyWhole Body Dual XRay Absorptiometry to Determine Body Composition

Policy CodePolicy N/A

Change TypeNo material change

Effective DateMar 1, 2025

Next Review DateNov 5, 2025

Key ActionDo not bill members for DXA body composition studies determined to be not medically necessary unless prior written agreement is obtained.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Not coveredNot covered for Medicare Advantage/Commercial

76499Not covered CPT

InsufficientEvidence status

NonePrior authorization

39References

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria

inv-01: Not covered / Not medically necessary

Covered when ALL of the following are met:

Policy stance: Dual-energy x-ray absorptiometry body composition studies are considered not covered for Medicare Advantage Plans and not medically necessary for Commercial Products as the evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

No studies identified that used DXA findings to guide patient management; evidence primarily research settings.

The use of DXA for bone mineral density assessment and vertebral fracture assessment is outside the scope of this policy. This policy addresses whole-body DXA body composition studies and does not modify coverage or clinical recommendations for DXA when performed for bone mineral density assessment or for vertebral fracture assessment.

Dual-energy x-ray absorptiometry (DXA) body composition studies are not medically necessary for Commercial Products and are considered not covered for Medicare Advantage Plans because the available evidence is insufficient to show that DXA body composition testing improves net health outcomes. The evidence base consists largely of research and validation studies that did not use DXA results to guide patient management.

inv-19: Clinical scenarios where body composition measurement might be useful (informational only)

Informational only — potential clinical scenarios where body composition measurement may provide useful information:

Potential clinical uses described in evidence review: DXA may be useful to evaluate undernourished patients and those with conditions such as anorexia nervosa or cachexia, assess patients undergoing treatments (eg, antiretroviral therapy, bariatric surgery), evaluate risk related to visceral fat versus total body fat (cardiometabolic risk), assess changes related to growth, development, or aging (eg, infancy, childhood, sarcopenia), and evaluate situations where BMI may be discordant with true fat mass (eg, body-building, edema).

Descriptive; not an authorization for coverage.

inv-20: Clinical and research indications supported by cited literature

Clinical and research indications supported by cited literature (informational):

Literature-supported indications: DXA-derived body composition measures are reported in research and clinical assessments across cancer (eg, associations of muscle mass with outcomes), chronic liver disease and cirrhosis (sarcopenia assessment), neuromuscular disorders (eg, facioscapulohumeral and Duchenne muscular dystrophies), obesity and bariatric surgery follow-up (visceral adipose tissue estimation), inflammatory bowel disease, and anorexia nervosa; referenced studies and practice parameters are cited in the evidence base.

Not Covered Services

Whole-body DXA body composition studies, billed using the unlisted diagnostic radiographic procedure code 76499, are not covered for Medicare Advantage Plans and are not medically necessary for Commercial Products. Providers should not expect coverage for services reported with this code when performed for whole-body DXA body composition assessment.

When a service is determined to be a non-covered benefit or not medically necessary under a member's subscriber agreement, the provider may not bill the member for that service unless the member has been informed in advance and has provided written agreement to self-pay. Verify member benefits and any applicable prior authorization or billing requirements with the member's Evidence of Coverage, subscriber agreement, or by contacting the provider call center.

Coding

Not covered / Not medically necessary CPT codesCPTNot Covered

76499

Unlisted diagnostic radiographic procedure

DXA body composition studies for whole-body assessment are explicitly designated in this policy as not covered for Medicare Advantage Plans and not medically necessary for Commercial Products. Because of this coverage stance, claims for these services may be denied. If a service is denied as not medically necessary or as a non-covered benefit, providers must follow the policy guidance regarding member notification and may not charge the member unless prior written agreement to self-pay was obtained.

Provider Actions & Billing Guidance

Prior Authorization

Prior authorization not applicable. Prior authorization is not required for services under this policy.

Documentation Required

Verify Benefits & Eligibility

Benefit verification required. Benefits and coverage may vary between groups/contracts; providers must verify member-specific benefits and eligibility before scheduling or performing services.

Refer to the member's Evidence of Coverage or Subscriber Agreement for applicable Radiology/Diagnostic Imaging benefits
Contact the BCBSRI provider call center for member-specific eligibility and benefit details

Background

Whole-body dual-energy x-ray absorptiometry (DXA) uses low-dose x-rays at two energy levels to estimate body composition, including fat mass, lean mass, and bone mass. DXA can produce total and regional measurements (for example, arms, legs, and trunk) and is commonly used in research and clinical assessments to quantify these compartments. However, studies reviewed for this policy were primarily research-based and did not demonstrate that DXA body composition measurements were used to change patient management or improve clinical outcomes.

Definitions

DXA definition — Dual-energy x-ray absorptiometry definition and purpose

DefinitionDual-energy x-ray absorptiometry (DXA) is an imaging modality that uses low-dose x-rays at two different energy levels to estimate bone mineral content and soft tissue composition (fat and lean mass).

Primary purposeMeasure lean tissue mass, total and regional body fat, and bone density using differential attenuation of two x-ray energies.

Measurement approachDXA systems generate x-rays at two energies and use the differential attenuation to estimate bone mineral content and soft tissue composition; soft tissue measurements are obtained only in regions without bone.

Regional analysisDXA can determine body composition in defined regions (eg, arms, legs, trunk) and provide regional as well as whole-body measures.

Limitations/assumptionsDXA-based body composition assumes constant hydration of fat-free mass (typically 73%), though hydration can vary from ~67% to 85%, affecting estimates.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyWhole Body Dual XRay Absorptiometry to Determine Body Composition

Policy CodePolicy N/A

Change TypeNo material change

Effective DateMar 1, 2025

Next Review DateNov 5, 2025

Key ActionDo not bill members for DXA body composition studies determined to be not medically necessary unless prior written agreement is obtained.

SourceLink

On This Page

Denial Risk

Coverage Denial Risk — DXA Body Composition

Coverage and medical necessity limitations. Dual-energy x-ray absorptiometry (DXA) body composition studies are not covered for Medicare Advantage Plans and are considered not medically necessary for Commercial Products.

Billing Rule

Potential Denial / Member Liability

Provider billing for non-covered or not medically necessary services. If a service is determined to be not medically necessary or a non-covered benefit, providers may not bill or collect payment from the member unless the member was informed in advance and provided written agreement to accept financial responsibility.

Providers should obtain prior written agreement from the member if planning to bill them for non-covered or not medically necessary services
Check provider participation agreements for applicable provisions

Note

Coding — Not Covered

Coding guidance — not covered code. The following CPT code is considered not covered for Medicare Advantage Plans and not medically necessary for Commercial Products.

CPT 76499 — Unlisted diagnostic radiographic procedure (not covered / not medically necessary)

Note

Provider action reminders. Verify member benefits and eligibility, confirm prior authorization requirements (if any) with the payer, and obtain written member agreement before providing services that may be non-covered or not medically necessary.

Body composition measurement — definition and intended use

DefinitionBody composition measurement is the quantification and assessment of proportions of specific body compartments such as fat mass, lean mass (bones, tissues, organs, muscles), and bone mass.

Intended clinical usesMay inform diagnosis, prognosis, or therapy beyond standard metrics (eg, weight or BMI) by identifying contributions of individual compartments.

Potential clinical applicationsEvaluate undernourished patients or those with disease-related wasting (eg, anorexia nervosa, cachexia); assess visceral fat-related cardiometabolic risk; monitor changes related to growth, aging (eg, sarcopenia), or disease; evaluate discordance between BMI and true fat mass (eg, bodybuilding, edema).

Research vs clinical useThese measurements have been most frequently utilized for research, and clinical utility for improving net health outcomes is not established in this policy's evidence review.

Methodological noteMultiple techniques exist (anthropometrics, bioelectrical impedance, underwater weighing, DXA), each relying on underlying assumptions and formulas that introduce variability across populations.

DXA (whole-body) — definition and measures including visceral adipose tissue estimates

Whole-body DXA definitionWhole-body DXA uses low-dose x-rays at two energy levels to estimate fat mass, lean tissue mass, and bone density across the entire body and in defined regions.

Measures reportedEstimates include total and regional fat mass, lean body mass (fat-free mass), and bone mineral content/density; regional measures typically include arms, legs, and trunk.

Visceral adipose tissue (VAT) estimationDXA-derived estimates of visceral adipose tissue have been used and studied (eg, validity studies cited), though methods and proprietary algorithms vary by manufacturer.

Technical constraintWhen only two x-ray energies are used, only two tissue compartments can be directly measured; soft tissue measurements (fat and lean) are valid only in areas without bone present.

Assumptions affecting accuracyDXA body composition calculations rely on assumptions such as constant hydration of fat-free mass (commonly 73%), but hydration can vary (67%–85%) and affect estimates.